505 related articles for article (PubMed ID: 18055102)
1. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
[TBL] [Abstract][Full Text] [Related]
2. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis.
Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Petropoulou O; Zis V; Sfagos C; Vassilopoulos D
In Vivo; 2008; 22(1):137-41. PubMed ID: 18396796
[TBL] [Abstract][Full Text] [Related]
3. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
Neurol Sci; 2003 Nov; 24(4):290-2. PubMed ID: 14658053
[TBL] [Abstract][Full Text] [Related]
4. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
[TBL] [Abstract][Full Text] [Related]
5. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
[TBL] [Abstract][Full Text] [Related]
6. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS.
Ajroud-Driss S; Saeed M; Khan H; Siddique N; Hung WY; Sufit R; Heller S; Armstrong J; Casey P; Siddique T; Lukas TJ
Amyotroph Lateral Scler; 2007 Oct; 8(5):305-9. PubMed ID: 17852022
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis.
Bruno R; Vivier N; Montay G; Le Liboux A; Powe LK; Delumeau JC; Rhodes GR
Clin Pharmacol Ther; 1997 Nov; 62(5):518-26. PubMed ID: 9390108
[TBL] [Abstract][Full Text] [Related]
8. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
[TBL] [Abstract][Full Text] [Related]
9. [Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis].
Roch-Torreilles I; Camu W; Hillaire-Buys D
Therapie; 2000; 55(2):303-12. PubMed ID: 10967703
[TBL] [Abstract][Full Text] [Related]
10. [Riluzole as a treatment for amyotrophic lateral sclerosis].
Borrás-Blasco J; Plaza-Macías I; Navarro-Ruiz A; Perís-Martí J; Antón-Cano A
Rev Neurol; 1998 Dec; 27(160):1021-7. PubMed ID: 9951030
[TBL] [Abstract][Full Text] [Related]
11. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
[TBL] [Abstract][Full Text] [Related]
12. Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Kwieciński H
Acta Neurol Scand; 2002 Jul; 106(1):39-43. PubMed ID: 12067327
[TBL] [Abstract][Full Text] [Related]
13. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid.
Perry TL; Krieger C; Hansen S; Eisen A
Ann Neurol; 1990 Jul; 28(1):12-7. PubMed ID: 2375629
[TBL] [Abstract][Full Text] [Related]
14. [Etiological drug therapy for amyotrophic lateral sclerosis].
Cintas P
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
[TBL] [Abstract][Full Text] [Related]
15. Riluzole and ALS therapy.
Hugon J
Wien Med Wochenschr; 1996; 146(9-10):185-7. PubMed ID: 8873431
[TBL] [Abstract][Full Text] [Related]
16. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
Dib M
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
[TBL] [Abstract][Full Text] [Related]
17. Riluzole is a potent drug to protect neonatal rat hypoglossal motoneurons in vitro from excitotoxicity due to glutamate uptake block.
Cifra A; Nani F; Nistri A
Eur J Neurosci; 2011 Mar; 33(5):899-913. PubMed ID: 21324003
[TBL] [Abstract][Full Text] [Related]
18. The ALS/MND prevalence in Sweden estimated by riluzole sales statistics.
Nygren I; Antonova K; Mattsson P; Askmark H
Acta Neurol Scand; 2005 Mar; 111(3):180-4. PubMed ID: 15691287
[TBL] [Abstract][Full Text] [Related]
19. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole.
Sívori M; Rodríguez GE; Pascansky D; Sáenz C; Sica RE
Medicina (B Aires); 2007; 67(4):326-30. PubMed ID: 17891927
[TBL] [Abstract][Full Text] [Related]
20. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers.
Levine TD; Bowser R; Hank N; Saperstein D
Amyotroph Lateral Scler; 2010 Dec; 11(6):514-9. PubMed ID: 20839903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
